Contents:

Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in royalty financing dealmaking 2.1. Introduction 2.2. What is royalty financing 2.2.1. Trends in royalty financing deals since 2000 2.3. Reasons for entering into royalty financing partnering deals 2.4 The emergence of royalty asset purchase deals 2.4.1. Primary players in royalty asset purchase deals 2.4.2. Recent royalty asset purchase deals 2.4.3. The role of bigpharma in royalty buyback 2.4.4. The future of royalty asset purchase deals Chapter 3 – Overview of royalty financing deal structure 3.1. Introduction 3.2. Anatomy of a royalty asset purchase agreement 3.3. Example royalty financing agreements 3.3.1. Case study 1: Emory University – Gilead Sciences – Royalty Pharma – July 2005 3.3.2. Case study 2: Enzon – Drug Royalty – August 2007 3.3.3. Case study 3: Royalty asset: DRI Capital – NPS Pharmaceuticals – July 2007 3.3.4. Case study 4: Royalty asset: TPG – CV Therapeutics – April 2008 Chapter 4 – Leading royalty financing deals 4.1. Introduction 4.2. Top royalty asset deals by value Chapter 5 – Royalty financing agreement directory 2003-early 2010 5.1. Introduction 5.2. Company A-Z 5.3. By therapy area Accident/Hospital/Trauma Blood/Lymphatic System Cardiovascular Central nervous System Dermatology Gastrointestinal Genetic Genitourinary Autoimmune/Inflammatory Hormonal Infection Metabolism Musculoskeletal Oncology Respiratory Sensory Organ / Oral Health Delivery Diagnostics Chapter 6 – Comprehensive royalty financing directory 2003-early 2010 6.1. Introduction 6.2. Company A-Z Appendices: Appendix 1 – Royalty financing references Appendix 2 – Resources Appendix 3 – Deal type definitions Appendix 4 – Example royalty financing contract Table of figures: Figure 1: Definition of royalty assets Figure 2: Trends in royalty financing deal announcements, 2000-2008 Figure 3: Leading royalty asset investors Figure 4: Recent royalty asset purchase agreements Figure 5: Components of the royalty asset purchase deal structure Figure 6: Top royalty asset deals since 2003 Figure 7: Online partnering resources Figure 8: Deal type definitions Figure 9: Sample asset purchase agreement: TPG – CV Therapeutics – April 2008: Asset purchase agreement for 50% Lexiscan injection royalty stream